After licensing the rights from Purdue University to research, develop, manufacture and market naturally occurring ECM products for cardiovascular applications, and subsequently entering into a cross license agreement with Cook Biotech, CorMatrix began its acceleration. In 2005, the Company received its first FDA clearance and shifted its focus from development stage to an integrated research, development and commercial entity. With significant patent protection, the Company is poised to successfully expand its current line of products.